Hepatocellular carcinoma (HCC) is
the most common form of liver cancer and usually develops secondary to liver
cirrhosis, which poses a significant medical challenge. Systemic therapy is used for treatment of advanced disease, and this
setting is dominated by the small-molecule multitargeted agent sorafenib (Bayer HealthCare and Onyx Pharmaceuticals’ Nexavar), which gained
regulatory approval in 2007 in the United and Europe. Sorafenib remains the
only targeted therapy approved for treatment of HCC, underscoring the
complexity of developing drug therapies for treatment of this disease.
Furthermore, HCC is the third most common cause of cancer death
globally; hence, a high unmet need for more-efficacious and well-tolerated
therapies for treatment of this disease remains.
Questions Answered in This Report:
Emerging therapies are in development for treatment of advanced
HCC following disease progression on sorafenib. Which of these agents are
most likely to launch for treatment of this patient population? Which patients
will they most likely benefit?
Interviewed experts state that there is a need for additional
therapies for treatment of advanced HCC in the first-line setting. Are there
emerging drugs that could be used in this patient segment? Will any drugs
challenge sorafenib for patient share?
Drug development efforts are also focusing on early stages of the
disease. What classes of agents are most likely to launch in this setting?
What proportion of patients will be eligible for treatment with these emerging
Markets covered: United States, France, Germany, Italy,
Spain, United Kingdom.
Primary research: 8 country-specific interviews with
Epidemiology: Diagnosed incidence segmented by localized,
locally advanced, and advanced disease.
Population segments: Localized, locally advanced, advanced
first-line, and advanced second-line.
Emerging therapies: Phase II: 13 drugs; Phase III: 9